USD 1.2 billion
Report ID:
SQMIG35I2329 |
Region:
Global |
Published Date: February, 2025
Pages:
218
|Tables:
88
|Figures:
75
Global Inhaled Nitric Oxide Market size was valued at USD 1.2 billion in 2023 and is poised to grow from USD 1.29 billion in 2024 to USD 2.38 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).
A crucial chemical for maintaining multiorgan survival and vascular homeostasis is nitric oxide. Its antibacterial qualities, respiratory issues, and cardio-cerebrovascular benefits are all beneficial. Inhaled nitric oxide improves ventilation-perfusion matching and arterial oxygenation by expanding the circulating pulmonary arteries, which increases blood flow to the ventilated areas of the lungs. Supplementing with nitric oxide is a common practice among athletes and fitness enthusiasts. By improving blood flow, oxygen delivery, and muscle nutrient absorption, it improves exercise performance. The primary focus of the major industry actors is the pipeline connections that facilitate the transport of nitrogen, argon, hydrogen, carbon monoxide, and oxygen. The major actors in many end-user industries, such as the pharmaceutical and healthcare sectors, watch over the distribution process.
The increase in end-users around the world is anticipated to propel the inhaled nitric oxide market worldwide. The market for inhaled nitric oxide is expected to rise due to several factors, including rising awareness and acceptance of nitric oxide's use in the healthcare sector, rising rates of cardiovascular and respiratory disorders, technical developments, and research and clinical studies. The market is expected to grow as more medical professionals become aware of the benefits of inhaled nitric oxide and its usage rises. The need for inhaled nitric oxide will rise due to the increasing number of respiratory and cardiovascular diseases, as it will aid in therapy.
Market snapshot - 2025-2032
Global Market Size
USD 1.2 billion
Largest Segment
Gas
Fastest Growth
Delivery System
Growth Rate
7.9% CAGR
To get more reports on the above market click here to Buy The Report
Global Inhaled Nitric Oxide Market is segmented by Type, Product Type, Application, Strength, Product, End-user and region. Based on Type, the market is segmented into Pediatric and Adult. Based on Product Type, the market is segmented into Inhaled Nitric Oxide Delivery Systems, Consumables, Nitric Oxide Cylinders, Delivery Accessories and Others. Based on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), Tuberculosis Treatment, Malaria Treatment and Others. Based on Strength, the market is segmented into 100 ppm, 800 ppm and Others. Based on Product, the market is segmented into Disposables and System. Based on End-user, the market is segmented into Hospitals, Ambulatory Centers and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per categorization by product type, the market is classified into gas and delivery system. Among these, gas types earned the largest share and continue to dominate the market. There is a lot of innovation and use of inhaled nitric oxide in the medical industry in the global market. Gas-inhaled nitric oxide is being used more and more to treat ailments such as respiratory distress syndrome and pulmonary hypertension, demonstrating its effectiveness and adaptability. Its expanding significance in clinical settings is shown by its use in neonatal care and as an adjuvant therapy for respiratory disorders. This pattern points to a bright future for inhaled nitric oxide as a treatment choice, which will fuel market growth.
Due to many variables, the inhaled nitric oxide delivery system is expected to develop at the fastest rate in the worldwide inhaled nitric oxide market. There is an increasing need for efficient treatment alternatives due to the rising prevalence of respiratory conditions such pulmonary hypertension and chronic obstructive pulmonary disease (COPD). The inhalation of nitric oxide propels the market's expansion at an accelerated pace since it provides a focused and effective delivery route with low systemic adverse effects and a speedy commencement of action.
The global inhaled nitric oxide market is changing due to advancements in malaria and respiratory illnesses. Inhaled nitric oxide has shown promise in respiratory care as an additional therapy for both chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS). It can lower pulmonary hypertension and increase oxygenation. Furthermore, new studies demonstrate how effective it is in preventing lung problems linked to malaria, providing a fresh method of treating this potentially fatal form of illness and broadening its use in the treatment of infectious diseases.
Acute respiratory distress syndrome (ARDS) and asthma and COPD are expected to have the quickest rates of growth in the global inhaled nitric oxide market as of the pressing demand for efficient treatment solutions and the rising prevalence of these conditions. As a treatment for these ailments, inhaled nitric oxide exhibits encouraging outcomes, providing bronchodilatory effects in COPD and asthma and enhancing oxygenation and pulmonary vascular resistance in acute respiratory distress syndrome (ARDS). The need for inhaled nitric oxide in the treatment of various respiratory illnesses is anticipated to rise sharply, propelling market expansion, as personalized medicine and tailored therapies gain more attention.
To get detailed analysis on other segments, Request For Free Sample Report
Throughout the anticipated period, North America is anticipated to maintain its prominent position in the global inhaled nitric oxide market. This is since there are recognized organizations for research and development as well as a modern healthcare infrastructure. To deliver inhaled nitric oxide therapy, North America offers sophisticated healthcare facilities, including clinics and hospitals, as well as the knowledge and resources to do so. During the anticipated period, the inhaled nitric oxide market is expected to grow at the quickest rate in Europe. This is due to the presence of significant regional players, continuing research, and clinical trials regarding the safety and effectiveness of inhaled nitric oxide. In Europe, pulmonary hypertension is a prevalent ailment that impacts many people.
Regional analyses show that the Middle East and Africa (MEA), Latin America, and Asia Pacific are the three regions where the global inhaled nitric oxide market is growing at the fastest rate. The growing healthcare infrastructure and increased incidence of respiratory illnesses in Asia Pacific are fueling market expansion. With rising awareness and healthcare spending, Latin America is seeing a rise in the use of cutting-edge medical treatments, such as inhaled nitric oxide. Due to the high prevalence of respiratory ailments in the MEA region, there is a growing demand for effective respiratory treatments, which has resulted in a quick uptake of inhaled nitric oxide therapies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
To Combat Against Respiratory Diseases
Advancement in Respiratory Care
Supervisory Hurdles
Availability of Nitric Oxide Gas Being Limited
Request Free Customization of this report to help us to meet your business objectives.
Several significant worldwide firms vying for market supremacy define the competitive landscape of the global inhaled nitric oxide market. To improve their position in the industry, major firms like Novoteris, Linde plc, Praxair Inc., Mallinckrodt Pharmaceuticals, and Air Liquide are actively working on new products, forming strategic alliances, and merging. To take advantage of the rising demand for inhaled nitric oxide therapy globally, these companies are concentrating on broadening their product offerings and geographic reach.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the rising incidence of respiratory diseases is driving the global market for inhaled nitric oxide, and as these illnesses continue to have an influence on people's lives, so too will demand for this therapy. The market for inhaled nitric oxide is expected to rise as improvements in respiratory care continue to make it a viable therapy choice for ailments like pulmonary hypertension, chronic obstructive pulmonary disease, and acute respiratory distress syndrome (ARDS). Inhaled nitric oxide products have regulatory obstacles, such as the necessity for standardization and approval, which hinder innovation and postpone the goods' entry into the market. Furthermore, the scalability of inhaled nitric oxide therapy is hampered by limited availability of nitric oxide gas due to intricate manufacturing procedures and specialized infrastructure, which may hinder market expansion.
Major worldwide players contending for market supremacy, including Novoteris, Linde plc, Praxair Inc., Mallinckrodt Pharmaceuticals, and Air Liquide, form the competitive landscape of the global inhaled nitric oxide market. To strengthen their position in the market and take advantage of the increasing demand for inhaled nitric oxide therapy globally, these firms priorities innovation, strategic alliances, and mergers. They also place a strong emphasis on expanding their product portfolios and geographic reach. By encouraging the use of inhaled nitric oxide to reduce symptoms, government and non-government programmes to promote knowledge of asthma—like the CDC's NACP programme sponsoring patient education in 2021—are generating more income and may even spur market expansion in the area.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 1.2 billion |
Market size value in 2032 | USD 2.38 billion |
Growth Rate | 7.9% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Inhaled Nitric Oxide Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Inhaled Nitric Oxide Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Inhaled Nitric Oxide Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Inhaled Nitric Oxide Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Inhaled Nitric Oxide Market size was valued at USD 1027 Million in 2023 and is poised to grow from USD 1108.65 Million in 2024 to USD 1894.52 Million by 2032, growing at a CAGR of 7.95% during the forecast period (2025-2032).
Several significant worldwide firms vying for market supremacy define the competitive landscape of the global inhaled nitric oxide market. To improve their position in the industry, major firms like Novoteris, Linde plc, Praxair Inc., Mallinckrodt Pharmaceuticals, and Air Liquide are actively working on new products, forming strategic alliances, and merging. To take advantage of the rising demand for inhaled nitric oxide therapy globally, these companies are concentrating on broadening their product offerings and geographic reach. 'Perma Pure LLC (US)', 'Merck KGaA (Germany)', 'Zylo Therapeutics Inc. (US)', 'HALMA PLC (UK)', 'Pieris Pharmaceuticals (US)', 'Air Liquide Healthcare (France)', 'Bellerophan Therapeutics Inc. (US)', 'Mallinckrodt Pharmaceuticals (Novoteris) (US)', 'Matheson Tri-Gas Inc. (US)', 'BOC Healthcare (UK)', 'Vero Biotech (US)', 'Nu-Med Plus Inc. (US)', 'Praxair Distribution Inc. (US)', 'LINDE PLC (UK)', 'Beyond Air', 'Taiyo Nippon Sanso Corporation', 'Praxair, Inc. (now part of Linde plc)', 'Novoteris, LLC', 'Nu-Med Plus, Inc.'
The market for inhaled nitric oxide is significantly driven by the rising prevalence of respiratory illnesses. The need for inhaled nitric oxide as a therapy option is anticipated to increase if these disorders continue to impact many people globally. Exposure to air pollution, cigarette smoke, and occupational risks are examples of environmental contaminants that can have a substantial impact on respiratory health and raise the chance of acquiring respiratory disorders. The ageing population's weakening immune systems and inherent changes in lung function make them more vulnerable to respiratory diseases. It is anticipated that the prevalence of respiratory illnesses would increase as the world's population ages.
Growing Impact of Asthma and COPD: Among the most prevalent respiratory illnesses impacting the public are asthma and COPD, both of which can be fatal and impair a patient's daily ability to breathe. Chronic asthma is a disorder that causes the lungs' air passageways to expand and constrict, which results in attacks of dyspnea, bronchospasm, and reversible airflow blockage. A significant increase in cigarette usage exacerbates the symptoms of COPD and asthma. Furthermore, because of increased industrialization, there are now more occurrences of COPD and asthma, which could drive up demand for inhaled nitric oxide during the projection period.
Throughout the anticipated period, North America is anticipated to maintain its prominent position in the global inhaled nitric oxide market. This is since there are recognized organizations for research and development as well as a modern healthcare infrastructure. To deliver inhaled nitric oxide therapy, North America offers sophisticated healthcare facilities, including clinics and hospitals, as well as the knowledge and resources to do so. During the anticipated period, the inhaled nitric oxide market is expected to grow at the quickest rate in Europe. This is due to the presence of significant regional players, continuing research, and clinical trials regarding the safety and effectiveness of inhaled nitric oxide. In Europe, pulmonary hypertension is a prevalent ailment that impacts many people.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35I2329
[email protected]
USA +1 351-333-4748